Generic Abuse-Deterrent Opioids: Comparison To Brand Will Not Require Use Of Control

FDA final guidance recommends comparative pharmacodynamic studies for nasal and oral routes of abuse, simplifies statistical approach to show deterrence of generic is same as brand.